Ligand Pharmaceuticals Incorporated (LGND)
| Market Cap | 1.26B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 17.71M |
| EPS (ttm) | 3.03 |
| PE Ratio | 23.43 |
| Forward PE | 15.88 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 152,955 |
| Open | 69.46 |
| Previous Close | 69.89 |
| Day's Range | 69.17 - 71.01 |
| 52-Week Range | 49.24 - 94.57 |
| Beta | 0.92 |
| Analysts | Strong Buy |
| Price Target | 116.33 (+63.85%) |
| Earnings Date | May 7, 2024 |
About LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for LGND stock is "Strong Buy." The 12-month stock price forecast is $116.33, which is an increase of 63.85% from the latest price.
News
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2024 financial results after the close of the U.S. financial market...
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
LONDON--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partners at the University of Minnesota (UMN) and CURx Pharmaceuticals, Inc. presented new data on ...
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
JUPITER, Fla. & DURHAM, N.C.--(BUSINESS WIRE)--Ligand Pharmaceuticals (Nasdaq: LGND) today announced the launch of Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and the appointment of s...
Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a f...
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that effective March 1, 2024, Ligand's Human Capital Management and Compensation Committee approved the g...
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2023, and provided an operating forec...
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Eisai Co., Ltd. obtained marketing authorization approval in January 2024 from the Japan...
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed Richard Baxter to the role of Senior Vice President of Investment Operations, and Karen ...
Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report full year and fourth quarter 2023 financial results before the opening of the U.S. fi...
Iambic Therapeutics Announces New Research Published in Nature Machine Intelligence Demonstrating the Capabilities of Its Generative AI NeuralPLexer Technology to Predict Protein-Ligand Complex Structures
SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a biotechnology company developing novel therapeutics using its unique generative AI discovery platform, today announced the publication of research in...
Ligand Pharma's at-home skin treatment gets FDA approval
Ligand Pharmaceuticals' topical treatment for a viral skin infection has received approval from the U.S. health regulator, the company said on Friday, marking the first-ever at-home approved treatment...
U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administration (FDA) has approved ZELSUVMI™ (berdazimer topical gel, 10.3%) f...
20 favorite small-cap stocks for 2024 among Wall Street analysts
The 2023 stock-market rally has been led by the “Magnificent Seven” companies, which have driven an accelerating upward trend for the large-cap benchmark S&P 500. Shares of smaller and medium-sized co...
Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) hosted an Investor and Analyst Day in New York City earlier today. CEO Todd Davis and other members of Ligand's senior ma...
Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host its Investor and Analyst Day on Tuesday, December 12, 2023. Members of Ligand's senior management team will pro...
Ligand Reports Third Quarter 2023 Financial Results
SAN DIEGO--(BUSINESS WIRE)---- $LGND #earnings--Ligand reports third quarter 2023 financial results.
Ligand Acquires Royalty on Sanofi's TZIELD® for $20 Million
SAN DIEGO--(BUSINESS WIRE)--Ligand Acquires Royalty on Sanofi's TZIELD® for $20 Million.
Ligand To Report Third Quarter 2023 Financial Results On November 8
SAN DIEGO--(BUSINESS WIRE)-- #earnings--Ligand To Report Third Quarter 2023 Financial Results On November 8.
Ligand Acquires Assets of Novan, Inc. for $12.2 Million
SAN DIEGO--(BUSINESS WIRE)--Ligand Acquires Assets of Novan, Inc. for $12.2 Million.
Ligand Appoints Martine Zimmermann to its Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Ligand Appoints Martine Zimmermann to its Board of Directors.
Ligand's Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
SAN DIEGO--(BUSINESS WIRE)--Ligand's Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze.
Ligand's Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control
SAN DIEGO--(BUSINESS WIRE)--Ligand's Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI.
Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio
SAN DIEGO--(BUSINESS WIRE)--Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio.
Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Ligand Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4).
Ligand Reports Second Quarter 2023 Financial Results
SAN DIEGO--(BUSINESS WIRE)-- #earnings--Ligand Reports Second Quarter 2023 Financial Results.